Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

"We are happy to sign an agreement to manufacture the oral COVID-19 antirviral medication, which is an urgent need of the hour, this is one...

Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...

The company earlier this month said the drug cut by 89% the chance of hospitalization or death for adults at risk of severe disease. The tr...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parente...

While the World Health Organisation (WHO) has warned against the general, unchecked use of Ivermectin, a study published in the American Jo...

The Institute of Nuclear Medicine and Allied Sciences, a DRDO lab, worked in partnership with Dr Reddy’s Laboratories to develop the drug, ...

According to Defence Research and Development Organisation (DRDO) statement, an anti-COVID-19 therapeutic application of the drug 2-deoxy-D...

Jubilant Pharma has successfully completed "safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India ...

Hospitals and pharmacists in major cities have reported acute shortage of the drug due to supply constraints and alleged hoarding.

In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, incl...

The Switzerland-based firm, which is a clinical-stage oncology-focussed biopharmaceutical company, has received approval for its investigat...